PaxMedica Inc. Common Sto...

AI Score

XX

Unlock

0.00
-0.00 (-100.00%)
At close: Mar 18, 2025, 2:54 PM
-100.00%
Bid n/a
Market Cap 25.13K
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.77
PE Ratio (ttm) n/a
Forward PE -0.03
Analyst n/a
Ask n/a
Volume 600
Avg. Volume (20D) 8,465
Open 0.00
Previous Close 0.00
Day's Range 0.00 - 0.00
52-Week Range 0.00 - 1.19
Beta -0.56

About PXMD

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomi...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2022
Employees 6
Stock Exchange OTC
Ticker Symbol PXMD
Full Company Profile